SOPH — SOPHiA GENETICS S.A. stock price, charts and financials

QT71SOPHiA GENETICS S.A.

SOPHiA GENETICS S.A. (NASDAQ: SOPH) is a Healthcare company in the Medical - Healthcare Information Services industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
8.53
+0.55+6.89%
OverviewShort InterestFilings
SOPHQT71SOPHiA GENETICS S.A.·NASDAQ
8.53+6.89%
News
Up 6.9% — SOPHiA Genetics: Scaling Phase Begins As U.S. And Pharma Monetization Inflect (SeekingAlpha).
Medium confidence
TA
Loading chart...
Signal & projected range
Insider selling clusterHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
PHR+0.39%$10.28HSTM-0.78%$29.19CTEV-5.45%$31.73NRC-5.35%$20.87TDOC-2.33%$6.28GDRX+0.29%$3.40OMDA+0.35%$19.83EVH-1.87%$3.67
Snapshot
Index-P/E-EPS (ttm)-1.15Insider Own9.70%Shs Outstand83.90MPerf Week12.09%
Market Cap715.63MForward P/E-EPS next Y-0.63Insider Trans-8.66%Shs Float72.00MPerf Month11.94%
Enterprise Value666.63MPEG-EPS next Q-0.20Inst Own-Short Float1.53%Perf Quarter62.79%
Income-80.00MP/S8.32EPS this Y18.43%Inst Trans-Short Ratio2.76Perf Half Y73.73%
Sales86.00MP/B8.62EPS next Y33.26%ROA-40.77%Short Interest1.10MPerf YTD82.66%
Book/sh0.99P/C6.63EPS next 5Y-ROE-136.71%52W High8.98 -5.01%Perf Year164.09%
Cash/sh1.29P/FCF-EPS past 3/5Y-ROIC-48.83%52W Low3.15 170.79%Perf 3Y238.49%
Dividend Est.-EV/EBITDA-Sales past 3/5Y17.06% 22.42%Gross Margin66.63%Volatility4.12% 5.58%Perf 5Y-51.03%
Dividend TTM-EV/Sales7.75EPS Y/Y TTM-21.05%Oper. Margin-85.01%ATR (14)0.44Perf 10Y-
Dividend Ex-Date-Quick Ratio2.55Sales Y/Y TTM32.31%Profit Margin-93.86%RSI (14)61.18Recom2.13
Dividend Gr. 3/5Y-Current Ratio2.69EPS Q/Q-178.79%SMA203.38%Beta0.92Target Price11.50
Payout0.00%Debt/Eq1.30Sales Q/Q27.78%SMA5018.71%Rel Volume2.45Prev Close7.98
Employees415LT Debt/Eq1.30EarningsNov 03SMA20054.73%Avg Volume494.29KPrice8.53
IPO DateJul 23, 2021Option/ShortYes / YesEPS/Sales Surpr.-23.79% 7.32%Net Debt/EBITDA0.70Volume1,210,879Change6.89%
Analyst Ratings
DateActionAnalystRatingTarget
Aug-05-26ReiteratedBTIGBuy$8.00 → $9.00
Aug-05-26ReiteratedHC Wainwright & Co.Buy$12 → $14
Jul-20-26InitiatedH.CBuy$12
Apr-15-26ReiteratedBTIGBuy$7.00 → $8.00
Mar-03-26ReiteratedBTIGBuy$5.00 → $7.00
Jan-26-26ReiteratedGuggenheimBuy$6.00 → $7.00
Mar-06-25ReiteratedBTIGBuy$6.00 → $5.00
Aug-07-24ReiteratedMorgan StanleyOverweight$5.00
Jun-27-24ReiteratedGuggenheim$6.00
Jan-03-23ReiteratedBTIGBuy$6.00
Latest News· Times ET
Sep-16-26
Sep-16-2606:33AM
SOPHiA Genetics: Scaling Phase Begins As U.S. And Pharma Monetization InflectSeekingAlpha
Sep-04-26
Sep-04-2609:08AM
SOPHiA GENETICS (SOPH) Stock Sees Modest Fair Value Lift After Q2 Guidance RaiseYahoo
Aug-27-26
Aug-27-2604:35AM
When Unusual Volume Isn't Noise: 3 Small-Caps Sending Signalsmarketbeat.com
Aug-24-26
Aug-24-2611:47PM
SOPHiA GENETICS (NASDAQ:SOPH) Sets New 1-Year High – What’s Next?defenseworld.net
Aug-18-26
Aug-18-2606:22PM
Tracking Al Gore's Generation Investment Management Portfolio - Q2 2026 UpdateSeekingAlpha
Aug-05-26
Aug-05-2607:39AM
SOPHiA GENETICS SA 2026 Q2 - Results - Earnings Call PresentationSeekingAlpha
Aug-04-26
Aug-04-2601:10PM
SOPHiA GENETICS SA (SOPH) Q2 2026 Earnings Call Transcriptseekingalpha.com
10:06AM
SOPHiA GENETICS Q2 Earnings Call Highlightsmarketbeat.com
02:45AM
SOPHiA GENETICS Reports Second Quarter 2026 Resultsprnewswire.com
02:15AM
SOPHiA GENETICS Enters Collaboration to Develop Companion Diagnostics for Precision Oncology Therapiesprnewswire.com
Jul-21-26
Jul-21-2604:00AM
SOPHiA GENETICS to Announce Financial Results for Second Quarter 2026 on August 4, 2026prnewswire.com
Jul-20-26
Jul-20-2604:39AM
This Charles Schwab Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For MondayBenzinga
Jun-18-26
Jun-18-2604:22AM
SOPHiA Genetics: Strong Growth Meets A Critical Execution PhaseSeekingAlpha
Jun-17-26
Jun-17-2604:44AM
Stock Market Today: Dow Futures Tumble, S&P 500, Nasdaq Gains As Investors Await FOMC Decision— Amkor, La-Z-Boy In Focus (UPDATED)Benzinga
04:03AM
Sophia Genetics, Ormat Technologies And Other Big Stocks Moving Lower In Wednesday's Pre-Market SessionBenzinga
Company

SOPHiA GENETICS S.A. operates as a specialized company within the healthcare technology sector. The firm provides the SOPHiA DDM platform, a cloud-native Software-as-a-Service (SaaS) solution engineered to analyze diverse multimodal datasets and various diagnostic inputs, thereby extracting valuable insights. This platform, together with its related offerings and services, is widely adopted by hospitals, laboratories, and biopharmaceutical organizations across the globe. Founded in 2011, SOPHiA GENETICS S.A. is headquartered in Saint-Sulpice, Switzerland.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
Total Revenue867765—————
Cost of Goods Sold Incl. D&A292921—————
Gross Profit584844—————
Selling, General and Administrative Excl. Other968576—————
Research and Development383434—————
Other Operating Expense-301—————
Operating Income-73-71-67—————
Interest Expense852—————
Unusual Expense
————————
Non-Operating Income (Expense)-1-37—————
Net Income Before Taxes-80-78-61—————
Income Taxes111—————
Consolidated Net Income-80-79-62—————
Net Income From Continuing Operations-80-79-62—————
Net Income-80-79-62—————
EPS (Recurring)-1.15-1.17-0.95—————
EPS (Basic, Before Extraordinaries)-1.15-1.17-0.95—————
EPS (Diluted)-1.15-1.17-0.95—————
EBITDA-65-64-51—————
Other After Tax Adjustments
————————
Stock Option Compensation Expense
————————
Price To Earnings Ratio
————————
Price To Sales Ratio7.344.123.12—————
Gross Margin67.4462.3467.69—————
Operating Margin-84.88-92.21-103.08—————
Net Margin-93.02-102.60-95.38—————
Shares Outstanding746866—————
Market Capitalization631318203—————
Operating Lease Expense
————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$9.81$7.89$5.96$4.04$2.12● Close Price0.00M0.30M0.61M0.91M1.22MUSD Trades VolumeSepOctNovDec2026FebMarAprMayJunJulAugSep
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Xu ZhenyuChief Scientific OfficerSep 14 '26Sale7.884,00031,538552,887Sep 16
Menu PhilippeChief Medical OfficerSep 14 '26Sale7.885,00039,417208,387Sep 16
Van Well DaanChief Legal OfficerSep 11 '26Sale7.636,16847,089338,884Sep 14
Camblong JurgiExecutive ChairmanSep 10 '26Sale7.668,50065,1203,435,822Sep 14
HIBBS KATHY LDirectorSep 08 '26Sale8.136,25050,81896,992Sep 10
Xu ZhenyuChief Scientific OfficerAug 27 '26Sale8.9110,00089,096556,887Aug 31
HIBBS KATHY LDirectorAug 25 '26Sale8.686,25054,233103,242Aug 26
Menu PhilippeChief Medical OfficerAug 25 '26Sale8.685,00043,397213,387Aug 26
Verma AbhimanyuChief Technology OfficerAug 24 '26Sale8.805,00044,000172,171Aug 26
Verma AbhimanyuChief Technology OfficerAug 19 '26Sale8.205,00041,000177,171Aug 26
Xu ZhenyuChief Scientific OfficerAug 21 '26Sale8.405,40845,447566,887Aug 21
Xu ZhenyuChief Scientific OfficerAug 20 '26Sale8.414,59238,609572,295Aug 21
Valente ManuelaChief People OfficerAug 19 '26Option Exercise3.2010,00032,000220,450Aug 21
Valente ManuelaChief People OfficerAug 19 '26Sale7.9410,00079,439210,450Aug 21
Xu ZhenyuChief Scientific OfficerAug 19 '26Sale7.9410,00079,427576,887Aug 21
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.